Showing results (1-10 of 88) with videos related to

Sort By:
Pageof 9
Cureus|March 23, 2019
Abscopal Effect, From Myth to Reality: From Radiation Oncologists' PerspectiveMelek Tugce Yilmaz, Aysenur Elmali, Gozde Yazici
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 20, 2023
Intracerebral de novo arterio-venous malformations as a side effect of bevacizumabAysenur Elmali, Rahsan Gocmen, Saadettin Kilickap, et al.
Cureus|January 17, 2019
The Synergistic Effect of Immune Checkpoint Blockade and Radiotherapy in Recurrent/Metastatic Sinonasal CancerGozde Yazici, Ibrahim Gullu, Mustafa Cengiz, et al.
Head & Neck|November 27, 2020
Parotid gland stem cells: Mini yet mightySezin Yuce Sari, Melek Tugce Yilmaz, Aysenur Elmali, et al.
Experimental Eye Research|October 24, 2021
Radiotherapy-induced alterations in vitreous humor: A new potential critical structureAysenur Elmali, Irem Koc, Samiye Yabanoglu Ciftci, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 3, 2022
Every other day stereotactic radiation therapy for the treatment of uveal melanoma decreases toxicityGozde Yazici, Hayyam Kiratli, Gokhan Ozyigit, et al.
Cureus|July 30, 2021
Does Combined Fractionated Stereotactic Radiotherapy and Immunotherapy Change the Outcome of Recurrent High-Grade Gliomas?Sezin Yuce Sari, Burak Yasin Aktas, Neyran Kertmen, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|September 23, 2025
The impact of vitreous humor: a new perspective on radiation-induced cataractogenesisEcem Yigit, Irem Koc, Gozde Yazici, et al.
Medical Dosimetry : Official Journal of the American Association of Medical Dosimetrists|May 20, 2021
Dosimetric comparison and secondary malignancy risk estimation for linac-based and robotic stereotactic radiotherapy in uveal melanomaFatih Biltekin, Gozde Yazici
The Prostate|March 26, 2024
The effect of dose-escalation radiotherapy with simultaneous-integrated-boost on the use of short-term androgen deprivation therapy in patients with intermediate risk prostate cancerCem Onal, Ozan Cem Guler, Gurcan Erbay, et al.
Pageof 9